FMT

CDI hospitalization in post-intestine transplant patients occurs commonly and is associated with a longer length of stay and higher costs during hospitalization. The CDI was the most common cause of readmission after the index admission of CDI in these patients.

Simon Baunwall and colleagues1 report a randomised, placebo-controlled trial of encapsulated faecal microbiota transplantation in patients with a first or second occurrence of Clostridioides difficile infection, following treatment with vancomycin. Existing guidelines allow consideration of faecal microbiota transplantation as an adjunct to antimicrobials in patients at first recurrence of C difficile infection if they are deemed to have a high risk of recurrence.2 However, Baunwall and colleagues' study raises questions as to whether all patients with C difficile infection could benefit from faecal microbiota transplantation.

Corrigendum to: Efficacy and Outcomes of Faecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease. Not only genetics, but the intestinal environment affected by gut microbiota is also the key to...

Major players in the microbiome market are MicroBiome Therapeutics LLC., Seres Therapeutics, Enterome Bioscience, Second Genome.......@ @ https://t.co/s3iAWrRQCu#Fecal #Microbiota #FMT #Drugs #Inflammatory #BowelDisease pic.twitter.com/KZ5jO67yH2— ramacharitbrc (@ramacharitbrc) January 6, 2023

Earlier is the leitmotif of a study reported in The Lancet Gastroenterology & Hepatology by Simon Baunwall and colleagues.1 High clinical efficacy and superiority of faecal microbiota transplantation was observed compared with the standard of care, vancomycin, administered for the first or second Clostridioides difficile infection episode, instead of after the recommended multiple recurrences.2 Due to a significantly lower rate of resolution in the placebo group, the trial was terminated before the designated number of patients was enrolled.

Dr. Martin Blaser and Dr. Gloria Dominguez-Bello talk to PEOPLE about their quest to save the human microbiome — before it's too late

Fecal microbiota transplantation 6 months before bariatric surgery did not reduce body weight in a small cohort of patients with obesity in Finland, according to study results published in JAMA Network Open. “The intestinal microbiota has aroused interest as a potential target for the treatment of obesity,” Perttu Lahtinen, MD, of the department of gastroenterology at

RBX2660 is the first ever live microbiota therapeutic approved by the FDA.

Chronic inflammation of the colon (colitis) is a known risk factor for inflammatory-driven colorectal cancers (idCRC), and intestinal microbiota has been implicated in the etiology of id-CRC. Manipulation of the microbiome is a clinically viable therapeutic approach to limiting id-CRC. To understand the microbiome changes that occur over time in id-CRC, we used a mouse model of idCRC with the treatment of azoxymethane (AOM) and dextran sodium sulfate (DSS) and measured the microbiome over time using 16S rRNA amplicon sequencing. We included cohorts where the microbiome was restored using cage bedding swapping and where the microbiome was depleted using antibiotics to compare to untreated animals. We identified consistent increases in Akkermansia in mice receiving horizontal microbiome transfer (HMT), while the control cohort had consistent longitudinal increases in Anaeroplasma and Alistipes . Additionally, fecal lipocalin-2 (Lcn-2) concentrations were elevated in unrestored animals compared to restored and antibiotic-treated counterparts following HMT. These observations suggest a potential role for Akkermansia, Anaeroplasma, and Alistipes in regulating colonic inflammation in id-CRC. ### Competing Interest Statement The authors have declared no competing interest.

About 20% of patients with ulcerative colitis don't achieve the expected efficacy with corticosteroid hormones. Fecal microbiota transplantation plus thalidomide was more effective than FMT alone in steroid-dependent ulcerative colitis https://t.co/7J60bD5wY9— GutMicrobiota Health (@GMFHx) December 30, 2022

Correcting the altered gut microbiome is an important goal in Clostridioides difficile management, but the matter is not addressed by mainstream treatments with antibiotics. This article focuses on where fecal microbiota transplantation and investigational microbiota-based therapeutics stand for C. difficile infection (Part 3)

Multiple studies have shown that fecal microbiota transplantation (FMT) is highly efficacious against recurrent Clostridioides difficile infection

Fecal microbiota transplantation (FMT) is a rapidly growing therapy aimed at reconstituting the dysbiotic microbiota of a patient with the beneficial stool microbiota of a healthy individual. The efficacy rates of FMT are very robust for recurrent Clostridioides difficile infection in both children …

#GMFH2023 has an excellent program in store for you. Don’t miss it!✅ Next-generation probiotics: single strains and consortia✅ Fecal microbiota transplantation✅ Diet and prebiotics✅ Microbiota-derived molecules@esnm_eu @AmerGastroAssn https://t.co/5u0d4X8K5r— GutMicrobiota Health (@GMFHx) December 28, 2022

Background Aging is a natural process that an organism gradually loses its physical fitness and functionality. Great efforts have been made to understand and intervene in this deteriorating process. The gut microbiota affects host physiology, and dysbiosis of the microbial community often underlies the pathogenesis of host disorders. The commensal microbiota also changes with aging; however, the interplay between the microbiota and host aging remains largely unexplored. Here, we systematically examined the ameliorating effects of the gut microbiota derived from the young on the physiology and phenotypes of the aged. Results As the fecal microbiota was transplanted from young mice at 5 weeks after birth into 12-month-old ones, the thickness of the muscle fiber and grip strength were increased, and the water retention ability of the skin was enhanced with thickened stratum corneum. Muscle thickness was also marginally increased in 25-month-old mice after transferring the gut microbiota from the young. Bacteria enriched in 12-month-old mice that received the young-derived microbiota significantly correlated with the improved host fitness and altered gene expression. In the dermis of these mice, transcription of Dbn1 was most upregulated and DBN1-expressing cells increased twice. Dbn1-heterozygous mice exhibited impaired skin barrier function and hydration. Conclusions We revealed that the young-derived gut microbiota rejuvenates the physical fitness of the aged by altering the microbial composition of the gut and gene expression in muscle and skin. Dbn1, for the first time, was found to be induced by the young microbiota and to modulate skin hydration. Our results provide solid evidence that the gut microbiota from the young improves the vitality of the aged. Video Abstract

Fecal microbiota transplant (FMT) is a therapeutic method that aims to restore normal gut microbial composition in recipients. Currently, FMT is approved in the USA to treat recurrent and refractory Clostridioides difficile infection and has been shown to have great efficacy. As such, signifi …

MTIG fully supports the continued vigilance of the FDA in regulating #FMT and the microbiome field to better assure that patients have access to safe and effective treatments. pic.twitter.com/DtCRF1Lr8N— MTIG (@MTIG_News) December 21, 2022

New research from the University of Virginia School of Medicine and collaborators reveals how microorganisms found in our guts can worsen dangerous C. difficile infections.

A fecal transplant is an unsetting concept but the treatment has a long history of usage and impressive efficacy. Now researchers are testing it widely.

Fecal microbiota transplantation ➕thalidomide was more effective than #FMT alone in steroid-dependent ulcerative colitis.#MedTwitter #GITwitter #IBD #microbiome https://t.co/p5mpfMziVQ pic.twitter.com/JDGHFymTvv— John Damianos, M.D. (@john_damianosMD) December 23, 2022

A fecal microbiota transplant (FMT) trial was halted early due to clear evidence the treatment was superior to placebo.

Fecal microbiota transplantation (FMT) is a potential treatment for many intestinal diseases. In dogs, FMT has been shown to have positive regulation effects in treating Clostridioides difficile infection (CDI), inflammatory bowel disease (IBD), canine parvovirus (CPV) enteritis, acute diarrh …

FMT was concluded to be an effective and safe therapy in pediatric and adolescent patients with C. difficile infection. Underlying comorbidities may impede the efficacy. A rigorous screening process of the donors is recommended prior to embarking on FMT. There is no universal and cost-effecti …

Tweets on twitter & posts on IG pertaining to microbiome go woefully under appreciated. FMTs literally saving lives, curing disease & improving the qualifying lives for thousands and it’s just the beginning 👊👊#fmt #FMTNews #microbiome #Health #healthy #cure https://t.co/uzRh883WPG— Sean OMara MD, JD (@DrSeanOMara) December 20, 2022

Last month, the FDA approved a fecal-based treatment for the first time. This approval is likely only the start of a promising future for prescription poop.

The Food and Drug Administration has approved the first fecal microbiota product to prevent recurrence of Clostridioides difficile infection (CDI) in people aged 18 years and older.Rebyota (fecal microbiota, li...

Inflammatory bowel disease (IBD) is a chronic intestinal mucosal inflammatory disease with complex etiology. Traditional anti-inflammatory treatment regimens have yielded unsatisfactory results. As research continues to deepen, it has been found that the gut microbiota of patients with IBD is genera …

MTIG Statements MTIG Statement on Future of Fecal Transplant Therapy and the Microbiome Industry The Microbiome Therapeutics Innovation Group (MTIG) notes the importance of the FDA’s finalization of previous guidance to enforce investigational new drug (IND) requirements to the use of FMT to treat CDI not responding to standard therapies.

This randomized clinical trial evaluates the effectiveness of fecal microbiota transplantation for weight loss in patients with obesity undergoing bariatric surgery.